Welcome to our dedicated page for Kiniksa Pharmaceuticals International, plc SEC filings (Ticker: KNSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Kiniksa Pharmaceuticals International, plc (KNSA) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, sourced in real time from the EDGAR system. As a Nasdaq‑listed biopharmaceutical issuer incorporated in England and Wales, Kiniksa uses these filings to report financial results, clinical and regulatory milestones, and other material corporate information.
Form 8‑K filings for KNSA document events such as quarterly financial results, investor presentations, and other significant updates. For example, Kiniksa has used Form 8‑K to furnish press releases announcing results for quarters ended June 30 and September 30, 2025, and to file an investor presentation used in meetings with investors and analysts. These filings also confirm that Kiniksa’s Class A ordinary shares trade on The Nasdaq Global Select Market under the symbol KNSA.
Investors can also review Kiniksa’s periodic reports, such as Forms 10‑K and 10‑Q, which typically contain detailed information on ARCALYST net product revenue, operating expenses, cash, cash equivalents, and short‑term investments, as well as risk factors and discussion of the company’s IL‑1‑focused portfolio. For a biopharmaceutical company like Kiniksa, these reports are central to understanding how ARCALYST commercialization and the development of KPL‑387 and KPL‑1161 affect overall financial performance and strategy.
On Stock Titan, AI‑powered summaries help interpret lengthy KNSA filings by highlighting key points in plain language, such as changes in revenue guidance, updates on the Phase 2/3 clinical trial of KPL‑387 in recurrent pericarditis, or disclosures about Orphan Drug Designation. Users can quickly locate references to IL‑1R1‑targeted programs, cardiovascular indications, and other topics without reading every page.
In addition, the filings page offers streamlined access to other important documents, including any proxy statements and beneficial ownership or insider‑related filings when available. Together, these SEC documents and AI‑generated insights give readers a structured view of Kiniksa’s regulatory history, financial reporting, and pipeline‑related disclosures.
Kiniksa Pharmaceuticals International ownership update: FMR LLC amended its Schedule 13G to report beneficial ownership of 6,787,700.23 shares of Class A common stock, representing 14.8% of the class. The filing lists sole dispositive power of 6,787,700.23 shares and references a power of attorney and Exhibit 99.
Kiniksa Pharmaceuticals International, plc Chief Medical Officer John F. Paolini reported an exercise-and-sell transaction in Class A Ordinary Shares. On May 1, 2026, he exercised options to acquire 58,424 shares at $10.36 per share and then sold the same number of shares in two open-market transactions at weighted average prices of $53.52 and $54.04. The sales were executed through a broker under a pre-arranged Rule 10b5-1 trading plan. Following the exercise, 29,670 share options remained outstanding and are fully vested, with an expiration date in February 2028.
Kiniksa Pharmaceuticals insider sale notice for Class A Ordinary Shares. The filing reports a broker-facilitated cashless exercise tied to an employee stock option on 05/01/2026 for 58,424 shares. It also reports a prior sale by John F. Paolini of 40,000 shares on 03/02/2026 for $1,792,970.00.
Kiniksa Pharmaceuticals International, plc reported that Chief Strategy Officer Eben Tessari has decided to resign to pursue another executive role in the life sciences industry. He will leave his officer role on May 15, 2026, but will continue supporting the company as a consultant.
Under a new Consulting Agreement effective May 15, 2026, Tessari will advise on strategic and operational matters and serve as a special advisor to the Science and Research Committee through May 15, 2027, with an option to renew. He will be paid $450 per hour, up to 20 hours per month, plus approved expenses. The company states his resignation is not due to any disagreement regarding its operations, policies, or practices.
Kiniksa Pharmaceuticals International, plc Chairman and CEO Sanj K. Patel reported an exercise-and-sale transaction in Class A Ordinary Shares. He exercised share options to acquire 48,565 shares at $30.93 per share and then sold 48,565 shares in an open-market transaction at a weighted-average price of $54.02 per share.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan dated October 31, 2025. Following these direct transactions, his directly held Class A Ordinary Shares were reduced to zero, while separate indirect holdings remain in several family trusts.
Kiniksa Pharmaceuticals International, plc director and CEO Sanj K. Patel reported a series of option exercises and related share sales in late April. He exercised options to acquire a total of 508,339 Class A Ordinary Shares at exercise prices of $10.36 and $30.93 per share, then sold the same number of shares in open-market transactions.
The reported sales occurred on April 28–30, 2026, at weighted average prices generally between $50.00 and about $54.23 per share, under a pre-arranged Rule 10b5-1 trading plan executed on October 31, 2025. After these transactions, filings show continued indirect ownership through family trusts, including 51,794, 109,795 and 76,174 Class A Ordinary Shares held by separate Patel family trusts, and remaining vested options for 48,565 shares at a $30.93 exercise price expiring in 2028.
Kiniksa Pharmaceuticals International, plc director Barry D. Quart executed an option exercise-and-sale transaction in Class A Ordinary Shares. He exercised options to acquire 13,099 shares at $14.33 per share and sold 13,099 shares at a weighted average price of $50.10 under a pre-arranged Rule 10b5-1 plan. The sale occurred in multiple broker-dealer trades between $50.00 and $50.725. After these transactions, he directly holds 12,546 shares and 13,237 remaining share options that are fully vested and exercisable, expiring on June 28, 2031.
Kiniksa Pharmaceuticals filed a Form 144 reporting proposed and recent sales of Class A Ordinary Shares. The report lists a broker payment for a cashless exercise on 04/28/2026 and discloses a prior sale of 7,278 shares by Sanj K Patel on 04/06/2026 for $363,949.
Kiniksa Pharmaceuticals International reported strong growth for the quarter ended March 31, 2026, driven by ARCALYST. Product revenue rose to $214.3 million, up from $137.8 million a year earlier, as more patients started treatment.
Net income increased to $22.6 million from $8.5 million, with diluted earnings per share rising to $0.27. Operating cash flow reached $50.2 million, and cash, cash equivalents and short-term investments totaled about $468.1 million, supporting ongoing R&D and commercialization.
The company continues to advance cardiovascular-focused programs, including KPL-387 in a Phase 2/3 trial for recurrent pericarditis and preclinical KPL-1161, while development of abiprubart has been discontinued as it explores strategic alternatives for that asset.
Kiniksa Pharmaceuticals International, plc reported strong first quarter 2026 results driven by ARCALYST. Net product revenue reached $214.3 million, representing 56% year-over-year growth, and total revenue was $214.3 million versus $137.8 million a year earlier. Net income rose to $22.6 million, up from $8.5 million, with diluted earnings per share increasing to $0.27 from $0.11.
The company raised its 2026 ARCALYST net sales guidance to a range of $930–$945 million, up from $900–$920 million, citing expanding adoption in recurrent pericarditis. Cash, cash equivalents, and short-term investments increased to $468.1 million as of March 31, 2026. Kiniksa highlighted portfolio progress, including Phase 2 KPL-387 recurrent pericarditis data expected in the second half of 2026 and initiation of a Phase 3 pivotal trial by year-end, as well as ongoing preclinical work on KPL-1161.